A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis - Trial NCT06383468
Access comprehensive clinical trial information for NCT06383468 through Pure Global AI's free database. This Phase 3 trial is sponsored by Akeso and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 420 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Akeso
Timeline & Enrollment
Phase 3
Apr 30, 2024
Jan 30, 2026
Primary Outcome
Percentage of subjects who achieved (Eczema Area and Severity Index) EASI-75
Summary
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study
 evaluating the efficacy and safety of AK120 injection in the treatment of patients with
 moderate to severe atopic dermatitis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06383468
Non-Device Trial